睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07848984,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Pathologically confirmed operable breast cancer with no prior systemic chemotherapy;

    入选标准第 2 条

  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1

    入选标准第 5 条

  4. Pregnancy or breastfeeding;

    排除标准第 5 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07848984,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years, regardless of sex;
  2. Pathologically confirmed operable breast cancer with no prior systemic chemotherapy;
  3. Planned to receive one of the following highly emetogenic chemotherapy (HEC) regimens. HEC refers to chemotherapy regimens associated with an expected incidence of vomiting of >90% in the absence of prophylactic antiemetic treatment, including anthracycline/cyclophosphamide-based regimens (AC, TC, or EC) and carboplatin-containing regimens (e.g., TCbH, TCbHP);
  4. Planned to receive triple antiemetic prophylaxis consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone. NK-1 receptor antagonists may include fosrolapitant, aprepitant, fosaprepitant, or other approved agents; 5-HT3 receptor antagonists may include palonosetron, ondansetron, or other approved agents;
  5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1
  6. Considered by the treating physician to be physically able to undergo and comply with the acupoint application procedure;
  7. Adequate major organ function and bone marrow function。

排除标准:Exclusion Criteria:

  1. Skin damage, ulceration, scarring, or severe infection at the intended application sites;
  2. Known history of severe allergy to any adhesive tape, patch materials, or herbal/other ingredients used in the study;
  3. Significant nausea (VAS ≥25 mm) within 24 hours before chemotherapy that, in the investigator's judgment, is not related to chemotherapy;
  4. Refractory vomiting due to non-chemotherapy-related causes, such as complete intestinal obstruction or severe vomiting caused by increased intracranial pressure secondary to brain metastases;
  5. Pregnancy or breastfeeding;
  6. Concomitant brain metastases, increased intracranial pressure, gastrointestinal obstruction, or other diseases that may cause nausea or vomiting;
  7. Severe hepatic, renal, or cardiac dysfunction, or other serious underlying diseases that, in the investigator's judgment, make the participant unsuitable for the study;
  8. Planned abdominal or pelvic radiotherapy within 7 days before randomization or during Days 1-7 of chemotherapy;
  9. Use of antiemetic medications within 48 hours before chemotherapy, except for the routine prophylactic antiemetic regimen specified in the triple antiemetic therapy, or use of other medications that may affect the assessment of nausea or vomiting;
  10. Severe psychiatric illness or cognitive impairment that prevents the participant from understanding the nausea/vomiting assessment scales or - complying with the 4-6-hour acupoint application procedure;
  11. Inability to take oral medications;
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

引自 ClinicalTrials.gov, NCT07848984, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07848984,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07848984